Innovaccer Gains CMS Approval for ACCESS Model, Targeting Chronic Care Management
Event summary
- Innovaccer accepted into CMS's ACCESS Model, launching July 2026.
- Company approved for both Early Cardio-Kidney-Metabolic (eCKM) and Cardio-Kidney-Metabolic (CKM) tracks.
- Zero-risk model allows health systems to earn new revenue without absorbing infrastructure or compliance obligations.
- Innovaccer's AI platform orchestrates end-to-end care management for chronic conditions affecting 2/3 of Medicare beneficiaries.
The big picture
Innovaccer's acceptance into the ACCESS Model positions it as a key player in Medicare's shift toward value-based care. The program represents a significant regulatory push to improve chronic care management for conditions affecting millions of beneficiaries, with CMS aligning payments directly with outcomes rather than service volume. Innovaccer's zero-risk model could accelerate adoption among health systems hesitant to invest in new infrastructure.
What we're watching
- Execution Risk
- Whether Innovaccer can deliver measurable results for health system partners in the first cohort.
- Market Expansion
- The pace at which Innovaccer expands into Musculoskeletal and Behavioral Health tracks.
- Regulatory Dynamics
- How CMS's outcome-aligned payment framework evolves under the ACCESS Model.
Related topics